Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03726515 · ClinicalTrials.gov registry record · Phase 1
CART-EGFRvIII + Pembrolizumab in GBM
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03726515: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT03726515 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03726515, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL CART-EGFRvIII T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2021-02-27 |
| Phase | Phase 1 |
What the finished NCT03726515 record still lists
NCT03726515 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03726515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03726515 about?
NCT03726515 is a clinical study titled "CART-EGFRvIII + Pembrolizumab in GBM". This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
What is the current status of trial NCT03726515?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-03-11. Estimated completion is 2021-02-27.
What interventions are being tested in trial NCT03726515?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), CART-EGFRvIII T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03726515?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03726515's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI